May 23 (Reuters) - Advisers to the U.S. Food and Drug
Administration on Thursday recommended for the approval of
Guardant Health's ( GH ) blood test to detect a cancer that
begins in the colon or rectum.
The panel voted seven-to-two in favor of benefits
outweighing risks when using the test called Shield for
colorectal cancer.
(Reporting by Puyaan Singh and Leroy Leo in Bengaluru; Editing
by Arun Koyyur)